Dapagliflozin and empagliflozin cut mortality from heart failure with reduced ejection fraction whether or not patients have ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a newer class of medications used to treat type 2 diabetes. These ...

Normally, filtered glucose is about 125 mg/min. Main action of SGLT2 inhibitors is the induction of glucosuria and osmotic diuresis. SGLT2 inhibitors reduce effectively fasting and postprandial ...

Diabetic retinopathy (DR) affects about 26 percent of people with diabetes. While many patients have an early form of DR, the condition can progress, posing the threat of irreversible vision loss.

SGLT2 inhibitors plus finerenone may have a protective effect against cardiovascular events in patients with HFpEF or HFmrEF.

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Saving hearts, one beat at a time Heart attacks are a leading cause of death and disability in Europe, and their effects ...

Related Disparities in Mortality Among Young Adults With Type 2 Diabetes" underscores the need for addressing disparities in ...